Introduction
Methods
Study subjects
Study protocol
Endpoints
BP measurements and laboratory tests
Statistical analyses
Results
Prescription of antihypertensive agents
Age (years) | 60.3 ± 11.5 |
Gender (male/female) | 158 (69%)/70 (31%) |
BMI (kg/m2) | 25.3 ± 4.4 |
Diabetes (n) | 35 (15%) |
Dyslipidemia (n) | 76 (33%) |
Heart disease (n) | 8 (4%) |
CKD stage (n) | |
1 (eGFR ≥90) | 23 (10%) |
2 (60 ≤ eGFR < 90) | 119 (52%) |
3 (30 ≤ eGFR < 60) | 70 (31%) |
4 (15 ≤ eGFR < 30) | 11 (5%) |
Changes in clinic and home BP
Changes in laboratory tests
Baseline | 6 months |
P value | |
---|---|---|---|
s-Cr (μmol/L) | 84.9 ± 34.5 | 89.3 ± 38.9 | <0.001 |
Na (mmol/L) | 141.5 ± 2.1 | 140.8 ± 2.0 | <0.001 |
K (mmol/L) | 4.3 ± 0.6 | 4.3 ± 0.6 | 0.940 |
LDL-C (mmol/L) | 3.0 ± 0.7 | 3.0 ± 0.7 | 0.356 |
HDL-C (mmol/L) | 1.5 ± 0.4 | 1.5 ± 0.4 | 0.118 |
TG (mmol/L) | 1.9 ± 1.5 | 1.9 ± 1.3 | 0.938 |
Hb (g/L) | 139 ± 18 | 139 ± 17 | 0.903 |
Ht (%) | 42.1 ± 4.5 | 41.8 ± 4.6 | 0.141 |
RBC (×1012/L) | 4.49 ± 0.5 | 4.47 ± 0.51 | 0.428 |
WBC (×109/L) | 6.2 ± 1.7 | 6.3 ± 1.8 | 0.508 |
Platelets (×109/L) | 232 ± 55 | 233 ± 55 | 0.670 |
eGFR(mL/min/1.73 m2) | 65.6 ± 21.2 | 63.4 ± 20.7 | <0.001 |